BTG3 and cancer: BTG3 expression was detectable in colorectal NNM (46.3%, 220/475), adenoma (57.9%, 73/126), primary cancer (82.0%, 396/484), and metastatic cancer in lymph node (80.0%, 120/150) and liver (81.0%, 17/21) respectively.